How Much Should Governments Pay For COVID-19 Monoclonal Antibody Therapies?

US government’s $450m manufacturing commitment for Regeneron’s antibody cocktail and Gilead’s price for remdesivir drive lower expectations on pricing for the antibody treatments, especially since it seems likely there could be several competing products.